New drug combo for advanced pancreatic cancer after first treatment
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug combo (cadonilimab plus either S-1 or capecitabine) for people with advanced pancreatic cancer that has not spread to other organs and who have already tried one standard treatment. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pancreatic ductal adenocarcinoma (a common type of pancreatic cancer).
- Your cancer is locally advanced, meaning it has not spread to distant organs like the liver or lungs.
- You have already received standard first-line treatment for your cancer and it is no longer working.
- You are between 18 and 80 years old and your overall health is fair to good (able to do light daily activities).
- You do not have other active cancers or serious health problems like uncontrolled infections or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (serplulimab and bevacizumab) plus two different chemotherapy regimens for people with advanced pancreatic cancer that has worsened after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer.
This trial tests a combination of three drugs—capecitabine (a chemotherapy pill), camrelizumab (an immunotherapy), and apatinib (a targeted therapy)—for people with advanced pancreatic cancer whose previous treatment stopped working or who cannot tolerate standard chemotherapy.
This trial tests a new combination of drugs (chiauranib, a PD-1 inhibitor, and two chemotherapy drugs) for people with a specific type of advanced pancreatic cancer who have not had prior treatment. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests a combination of three drugs (given through a vein and a pill) plus a chemotherapy infusion directly into your belly for stomach cancer that has spread to the lining of the abdomen. It specifically looks at a marker called Claudin 18.2 to see if this treatment works better for people with that marker.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.